Clinical Trials Logo

Borderline Personality Disorder clinical trials

View clinical trials related to Borderline Personality Disorder.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04095546 Withdrawn - Clinical trials for Borderline Personality Disorder (BPD)

Epigenetic Changes in Psychotherapy of Adolescents With Borderline Personality Pathology

Start date: April 2022
Phase:
Study type: Observational

The link between epigenetic changes as an effect of psychotherapy has been investigated recently. Genes investigated in these studies were brain-derived neurotrophic factor (BDNF), NR3C1, FKBP51, MAOA and GLUT1. Change in methylation of these genes could be a biomolecular mechanism of psychotherapy induced changes. This study project aims at providing evidence for a biological mechanism of personality disorder interventions in adolescence by investigating the link between epigenetic changes as an effect of psychotherapy. It investigates the correlation between changes in the methylation of the FKBP5 gene and psychotherapy induced changes in symptoms and functioning.

NCT ID: NCT03932656 Withdrawn - Clinical trials for Borderline Personality Disorder

Latent Toxoplasmosis in Females With Borderline Personality Disorder

Start date: January 1, 2021
Phase:
Study type: Observational

Borderline personality disorder is a common mental disorder with core features of affective dysregulation, impulsivity, and identity disturbance. Although this disorder is mostly understood as a result of a combination of biological factors (genes, temperament) and early aversive experiences (often of traumatic nature), recent data suggest that other factors may be important in its development and course. Preliminary findings show that patients with borderline personality disorder have higher prevalence of Toxoplasma seropositivity. This infection may manifest in symptoms such as affective dysregulation, aggression, suicidality, or anxiousness. As such, it may play a role in the psychopathology of the borderline personality disorder. The aim of this study is to explore the prevalence of Toxoplasma seropositivity in a sample of females with borderline personality disorder, its clinical correlates, and a potential impact on outcomes of an intensive six-week inpatient schema-therapeutic treatment. Results may enrich our understanding of this disorder and lead to improvements of the therapeutic approaches.

NCT ID: NCT03880071 Withdrawn - Clinical trials for Borderline Personality Disorder

DIalectical Behavior Therapy and Acceptance Commitment Therapy Short Program for BOrderLine persOnality Disorder

DIABOLO
Start date: November 30, 2019
Phase: N/A
Study type: Interventional

According to the World Health Organization 1 death by suicide occurs every 40 seconds, leading suicide prevention to one of the public health priority. Borderline personality disorder (BPD) is a common condition affecting 6% of the population. This disorder is characterized by unstable emotions, unstable mood, difficulties with relationship and feer of abandonment. BPD is also the psychopathology the most related to suicidal attempts. Indeed, up to 50% of the patients admitted to hospital after a suicide attempt are diagnosis with a BPD. Negative interpersonal events (events occurring between two people) are known as the main stressor that trigger a suicidal attempt. People with a BPD are highly sensitive to it. Unfortunately, patient care for this disorder is limited. Pharmacological strategies didn't show any efficacy and psychotherapies, although proven effective, are difficult to set up. As BPD is strongly related to suicidal attempts it appears to be a good model to study suicidal behavior. Thus, this study could improve knowledge in this field. Suicidal behavior in patients receiving the standard therapy (dialectic behavioural therapy: DBT) will be compared to patients receiving dialectical behavior therapy and acceptance commitment therapy (ACT). Clinical data reflecting how the participant is feeling will be collected as well.

NCT ID: NCT03139825 Withdrawn - Adolescent Behavior Clinical Trials

Connectivity and Social Cognition in Adolescent Girls With Borderline Personality Disorder, a Pilot Study

EEG-NIRS
Start date: February 22, 2017
Phase: N/A
Study type: Interventional

The disruption of social cognition associated with borderline personality disorder (BPD), and more specifically categorization of facial emotions, remains largely under-studied, despite the high frequency of this pathology in the clinical population. The first results differ from the observations made in adults and this confirms the relevance of studying this theme specifically in adolescence. On the cognitive level, there is a disturbance of the detection and the categorization of the facial emotions in the TPL. The characteristics of this disturbance and its possible association with an attack on the connectivity of the brain remain unknown in adolescence. No functional imaging studies are published in adolescent TPL. This pilot bimodal functional imaging study EEG-NIRS aims to collect preliminary and feasibility data to support a response to upcoming PHRC competitions and eventually offer a science thesis opportunity.

NCT ID: NCT02849431 Withdrawn - Clinical trials for Borderline Personality Disorder

Mindfulness for Intense Emotions: A Feasibility Trial

MindIE
Start date: July 2016
Phase: N/A
Study type: Interventional

This study explores the feasibility of a mindfulness-based intervention for people with a diagnosis of borderline personality disorder.

NCT ID: NCT02522143 Withdrawn - Suicide Clinical Trials

College Students Who Self-Harm

Start date: February 2014
Phase: N/A
Study type: Interventional

Study Aims/Objectives: This projects' Primary Aim is development of a Condensed DBT Stepped Care Model tailored to the unique requirements of students meeting sub-clinical diagnostic criteria for BPD (Borderline Personality Disorder) with its associated high rate of self-harm and suicide.

NCT ID: NCT00463775 Withdrawn - Alcohol Dependence Clinical Trials

Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The objective of the present study is to evaluate the efficacy of topiramate (250mg/day) versus placebo in decreasing aggression and reducing alcohol consumption in patients with borderline personality disorder (BPD) and alcohol dependence (AD).